A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7125 (2006.01) C12N 15/11 (2006.01) A61K 38/00 (2006.01) A61K 47/26 (2006.01)
Patent
CA 2426047
It has now been discovered that oligonucleotides which tend to form multimeric aggregates have greater toxicity in the aggregate form than in monomeric form. Thus, the present invention provides therapeutic oligonucleotide compositions of reduced in vivo toxicity, and a method for making such compositions, as well as a method for administration of the therapeutic oligonucleotide, where the therapeutic oligonucleotide in one that tends to form multimeric aggregates. Compositions containing such aggregate-forming oligonucleotides are treated by heating, preferably no more than 24 hours prior to administration, or using chemical species such as mannitol which disrupt aggregates.
Il a été découvert que les oligonucléotides tendant à former des agrégats multimères présentent une plus grande toxicité sous la forme d'agrégats que sous une forme monomère. Ainsi, la présente invention présente des compositions oligonucléotidiques thérapeutiques à toxicité in vivo réduite et une méthode de production de ces compositions, ainsi qu'une méthode d'administration de l'oligonucléotide thérapeutique, dans laquelle l'oligonucléotide thérapeutique tend à former des agrégats multimères. Les compositions contenant ces oligonucléotides formant des agrégats sont traitées par chauffage, de préférence pas plus de 24 heures avant administration, ou utilisation d'espèces chimiques telles que le mannitol rompant les agrégats.
Madden Thomas D.
Webb Murray S.
Inex Pharmaceuticals Corporation
Smart & Biggar
LandOfFree
Therapeutic oligonucleotides of reduced toxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic oligonucleotides of reduced toxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic oligonucleotides of reduced toxicity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1748103